Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria
| Filename | 174. Magerl et al, Randomised doubl...Miltefosine.JEADV2013.pdf |
| Filesize | 303.06 KB |
| Version | o.174 |
| Date added | June 6, 2020 |
| Downloaded | 0 times |
| Category | Original Work |
| Authors | Magerl, M., Rother, M., Bieber, T., Biedermann, T., Brasch, J., Dominicus, R., Hunzelmann, N., Jakob, T., Mahler, V., Popp, G., Schäkel, K., Schlingensiepen, R., Schmitt, J., Siebenhaar, F., Simon, J. C., Staubach, P., Wedi, B., Weidner, C., and Maurer, M. |
| Citation | Magerl, M., Rother, M., Bieber, T., Biedermann, T., Brasch, J., Dominicus, R., Hunzelmann, N., Jakob, T., Mahler, V., Popp, G., Schäkel, K., Schlingensiepen, R., Schmitt, J., Siebenhaar, F., Simon, J. C., Staubach, P., Wedi, B., Weidner, C., and Maurer, M.: Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2013: 27; e363-e369. |
| Corresponding authors | Maurer, M. |
| DocNum | O.174 |
| DocType | |
| Edition; Page | 27; e363-e369 |
| IF | 2.78 |
| Publisher | J. Eur. Acad. Dermatol. Venereol. |
| ReleaseDate | 2013 |
Background: Chronic spontaneous urticaria (CSU), a mast cell-driven condition, is debilitating, common, and hard to treat. Miltefosine, a lipid raft modulator, can inhibit mast cell responses in vivo.
Objective To study the safety and efficacy of systemic miltefosine treatment in CSU patients resistant to standard- dosed antihistamines.
Methods: In this investigator-initiated multicentre, randomized, double-blind, placebo-controlled study, CSU patients were treated for 4 weeks with daily doses of up to 150-mg miltefosine (n = 47) or placebo (n = 26). Disease activity was assessed using the urticaria activity score. Safety and tolerability of miltefosine were also assessed.
Results: After 4 weeks of treatment, Urticaria Activity Score (UAS7) levels were substantially more reduced in miltefosine-treated patients ()6.3 vs. )3.5 in placebo-treated patients; P = 0.05). Also, the number of weals, but not the intensity of pruritus, was significantly reduced in miltefosine-treated patients vs. placebo-treated patients (P = 0.02). In general, adverse events were frequent in both groups (miltefosine: 88%, placebo: 65% of patients) but mostly mild to moderate in severity. We did not observe any serious adverse events.
Conclusions: The results of this study indicate that miltefosine is an effective and safe treatment option for CSU patients who do not respond to standard-dosed antihistamines.
Received: 10 April 2012; Accepted: 27 July 2012
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.